Tumor targeting with a selective gelatinase inhibitorKOIVUNEN, E; ARAP, W; SORSA, T et al.Nature biotechnology. 1999, Vol 17, Num 8, pp 768-774, issn 1087-0156Article

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse modelARAP, W; PASQUALINI, R; RUOSLAHTI, E et al.Science (Washington, D.C.). 1998, Vol 279, Num 5349, pp 377-380, issn 0036-8075Article

Point mutations can inactivate in vitro and in vivo activities of p16^INK4a/CDKN2A in human gliomaARAP, W; KNUDSEN, E. S; WANG, J. Y et al.Oncogene (Basingstoke). 1997, Vol 14, Num 5, pp 803-809, issn 0950-9232Article

Functional analysis of wild-type and malignant glioma derived CDKN2Aβ alleles: Evidence for an RB-independent growth suppressive pathwayARAP, W; KNUDSEN, E; SEWELL, D. A et al.Oncogene (Basingstoke). 1997, Vol 15, Num 17, pp 2013-2020, issn 0950-9232Article

NG2 proteoglycan-binding peptides target tumor neovasculatureBURG, M. A; PASQUALINI, R; ARAP, W et al.Cancer research (Baltimore). 1999, Vol 59, Num 12, pp 2869-2874, issn 0008-5472Article

Replacement of the p16/CDKN2 gene suppresses human glioma cell growthARAP, W; NISHIKAWA, R; FURNARI, F. B et al.Cancer research (Baltimore). 1995, Vol 55, Num 6, pp 1351-1354, issn 0008-5472Article

A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formationLIN, S.-H; CHENG, C.-J; HU, M et al.Oncogene (Basingstoke). 2008, Vol 27, Num 39, pp 5195-5203, issn 0950-9232, 9 p.Article

Spare the rod and spoil the eyeARDEN, G. B; SIDMAN, R. L; ARAP, W et al.British journal of ophthalmology. 2005, Vol 89, Num 6, pp 764-769, issn 0007-1161, 6 p.Article

Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesisPASQUALINI, R; KOIVUNEN, E; KAIN, R et al.Cancer research (Baltimore). 2000, Vol 60, Num 3, pp 722-727, issn 0008-5472Article

Identification of receptor ligands with phage display peptide librariesKOIVUNEN, E; ARAP, W; RAJOTTE, D et al.The Journal of nuclear medicine (1978). 1999, Vol 40, Num 5, pp 883-888, issn 0161-5505Article